Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) CFO Adam Laponis sold 556 shares of the business's stock in a transaction on Tuesday, April 9th. The shares were sold at an average price of $33.16, for a total transaction of $18,436.96. Following the completion of the transaction, the chief financial officer now owns 74,444 shares of the company's stock, valued at $2,468,563.04. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Twist Bioscience Stock Up 2.6 %
Twist Bioscience stock opened at $32.68 on Friday. Twist Bioscience Co. has a 52-week low of $11.46 and a 52-week high of $43.21. The company has a fifty day simple moving average of $36.41 and a 200-day simple moving average of $29.63.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Friday, February 2nd. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $0.03. Twist Bioscience had a negative net margin of 78.44% and a negative return on equity of 32.16%. The business had revenue of $71.50 million during the quarter, compared to analyst estimates of $67.59 million. During the same quarter in the prior year, the firm earned ($0.74) earnings per share. The company's revenue for the quarter was up 31.8% compared to the same quarter last year. Equities analysts anticipate that Twist Bioscience Co. will post -3.17 EPS for the current fiscal year.
Institutional Investors Weigh In On Twist Bioscience
Massive breakthrough for options traders.
From WealthPress | Ad
A 34 year old man from central florida has uncovered a totally new way to trade options…
Already this year it’s allowed real people to capture top returns of 50%...
100%...
Even 200% overnight…
Without using technical patterns, momentum, A.I. or any of the other commonly used strategies…
Now, it’s important to mention that nothing is 100% perfect in terms of trading.
Click here to see this stunning development for yourself.
A number of large investors have recently modified their holdings of the business. Wellington Management Group LLP purchased a new stake in shares of Twist Bioscience during the fourth quarter worth $976,000. Virtu Financial LLC purchased a new stake in shares of Twist Bioscience in the fourth quarter valued at about $526,000. GSA Capital Partners LLP purchased a new stake in shares of Twist Bioscience in the fourth quarter valued at about $1,590,000. Mercer Global Advisors Inc. ADV grew its holdings in shares of Twist Bioscience by 16.7% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 26,019 shares of the company's stock valued at $959,000 after purchasing an additional 3,719 shares during the period. Finally, Barclays PLC grew its holdings in shares of Twist Bioscience by 4.1% in the fourth quarter. Barclays PLC now owns 253,986 shares of the company's stock valued at $9,363,000 after purchasing an additional 10,097 shares during the period.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on the stock. Scotiabank boosted their price target on shares of Twist Bioscience from $30.00 to $43.00 and gave the stock a "sector outperform" rating in a report on Monday, February 5th. The Goldman Sachs Group raised shares of Twist Bioscience from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $25.00 to $45.00 in a report on Wednesday, January 17th. Finally, Barclays cut their price target on shares of Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating for the company in a report on Wednesday.
View Our Latest Analysis on TWST
About Twist Bioscience
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
